Benign Conditions

Latest News

ELIMINATE trial: uUTI regimen demonstrates initial tolerability, efficacy
ELIMINATE trial: uUTI regimen demonstrates initial tolerability, efficacy

November 1st 2024

A rapid reduction in E coli in the urine was observed among 10 of 16 evaluable patients at 4 hours following the first treatment.

FDA approves oral sulopenem for uncomplicated urinary tract infection
FDA approves oral sulopenem for uncomplicated urinary tract infection

October 25th 2024

Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
FDA approves IDE for study evaluating underactive bladder device

October 15th 2024

Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
IC/BPS has more than 1 phenotype: A need for consensus to move forward

September 19th 2024

FDA Advisory Committee meets to discuss NDA of oral sulopenem for uUTI
FDA Advisory Committee meets to discuss NDA of oral sulopenem for uUTI

September 9th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.